RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsMIRASOL Conclusions
• MIRV is the first novel treatment to demonstrate a benefit in overall survival in platinum-resistant ovarian cancer in a phase 3 trial
• MIRV demonstrated statistically significant and clinically meaningful improvement in PFS, ORR, and OS compared to IC chemotherapy, with a differentiated safety profile consisting predominantly of low-grade ocular and gastrointestinal events
• MIRV is the first ADC for ovarian cancer with proven efficacy and is the only FDA approved biomarker-directed therapy for platinum-resistant ovarian cancer
• These data are practice-changing and position MIRV as a new standard of care for patients with FR-positive PROC